BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36625858)

  • 1. CD4/CD8 Ratio Recovery Among People Living With HIV Starting With First-Line Integrase Strand Transfer Inhibitors: A Prospective Regional Cohort Analysis.
    Han WM; Avihingsanon A; Rajasuriar R; Tanuma J; Mundhe S; Lee MP; Choi JY; Pujari S; Chan YJ; Somia A; Zhang F; Kumarasamy N; Tek Ng O; Gani Y; Chaiwarith R; Pham TN; Do CD; Ditangco R; Kiertiburanakul S; Khol V; Ross J; Jiamsakul A;
    J Acquir Immune Defic Syndr; 2023 Feb; 92(2):180-188. PubMed ID: 36625858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy.
    Fabbiani M; Borghetti A; Squillace N; Colafigli M; Taramasso L; Lombardi A; Rossetti B; Ciccullo A; Colella E; Picarelli C; Berruti M; Latini A; Montagnani F; Sambo M; Di Biagio A; Gori A; Di Giambenedetto S; Bandera A
    J Acquir Immune Defic Syndr; 2021 Jan; 86(1):119-127. PubMed ID: 33306566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study.
    Serrano-Villar S; Martínez-Sanz J; Ron R; Talavera-Rodríguez A; Fernández-Felix BM; Herrera S; Muriel A; Fanjul F; Portilla J; Muñoz J; Amador C; de Zárraga MA; Vivancos MJ; Moreno S;
    Lancet HIV; 2020 Aug; 7(8):e565-e573. PubMed ID: 32763219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study.
    Masiá M; Padilla S; Barber X; Sanchis M; Terol G; Lidón F; Gutiérrez F
    Medicine (Baltimore); 2016 Mar; 95(11):e3108. PubMed ID: 26986155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of first-line antiretroviral therapy regimens on the restoration of the CD4/CD8 ratio in the CNICS cohort.
    Herrera S; Fernandez-Felix BM; Hunt PW; Deeks SG; Sainz T; Heath SL; Achenbach CJ; Rodríguez B; Mathews C; Christopoulos K; Mayer K; Napravnik S; Moreno S; Serrano-Villar S
    J Antimicrob Chemother; 2020 Jun; 75(6):1604-1610. PubMed ID: 32211777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
    Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
    J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is immune recovery different depending on the use of integrase strand transfer inhibitor-, non-nucleoside reverse transcriptase- or boosted protease inhibitor-based regimens in antiretroviral-naive HIV-infected patients?
    Milanés-Guisado Y; Gutiérrez-Valencia A; Muñoz-Pichardo JM; Rivero A; Trujillo-Rodriguez M; Ruiz-Mateos E; Espinosa N; Roca-Oporto C; Viciana P; López-Cortés LF
    J Antimicrob Chemother; 2020 Jan; 75(1):200-207. PubMed ID: 31617904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight gain after antiretroviral therapy initiation in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
    Zhao X; Prajapati G; Tse J; Near AM; Kumar PN
    Curr Med Res Opin; 2023 Jul; 39(7):997-1006. PubMed ID: 37334707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency Virus Cohort Study.
    Sangaré MN; Baril JG; de Pokomandy A; Klein M; Thomas R; Tremblay C; Pexos C; Durand M; Chawla S; Laporte L; Trottier H
    Clin Infect Dis; 2023 Jun; 76(11):1879-1888. PubMed ID: 36722329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.
    Bourgi K; Rebeiro PF; Turner M; Castilho JL; Hulgan T; Raffanti SP; Koethe JR; Sterling TR
    Clin Infect Dis; 2020 Mar; 70(7):1267-1274. PubMed ID: 31100116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrase inhibitor-based regimens are related to favorable systemic inflammatory index and platecrit scores in people living with HIV (PLWH) up to 2 years.
    Şahin EA; Mavi D; Kara E; Sönmezer MÇ; İnkaya AÇ; Ünal S
    Postgrad Med; 2022 Aug; 134(6):635-640. PubMed ID: 35671079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight gain following switch to integrase inhibitors from non-nucleoside reverse transcriptase or protease inhibitors in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
    Tse J; Prajapati G; Zhao X; Near AM; Kumar PN
    Curr Med Res Opin; 2023 Sep; 39(9):1237-1246. PubMed ID: 37480288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
    Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
    Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral Regimens and CD4/CD8 Ratio Normalization in HIV-Infected Patients during the Initial Year of Treatment: A Cohort Study.
    De Salvador-Guillouët F; Sakarovitch C; Durant J; Risso K; Demonchy E; Roger PM; Fontas E
    PLoS One; 2015; 10(10):e0140519. PubMed ID: 26485149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration.
    Rein SM; Lodi S; Logan RW; Touloumi G; Antoniadou A; Wittkop L; Bonnet F; van Sighem A; van der Valk M; Reiss P; Klein MB; Young J; Jarrin I; d'Arminio Monforte A; Tavelli A; Meyer L; Tran L; Gill MJ; Lang R; Surial B; Haas AD; Justice AC; Rentsch CT; Phillips A; Sabin CA; Miro JM; Trickey A; Ingle SM; Sterne JAC; Hernán MA;
    Lancet HIV; 2023 Nov; 10(11):e723-e732. PubMed ID: 37923486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States.
    Rebeiro PF; Emond B; Rossi C; Bookhart BK; Shah A; Caron-Lapointe G; Lafeuille MH; Donga P
    J Int AIDS Soc; 2023 Jun; 26(6):e26123. PubMed ID: 37306118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrase inhibitors in late pregnancy and rapid HIV viral load reduction.
    Rahangdale L; Cates J; Potter J; Badell ML; Seidman D; Miller ES; Coleman JS; Lazenby GB; Levison J; Short WR; Yawetz S; Ciaranello A; Livingston E; Duthely L; Rimawi BH; Anderson JR; Stringer EM;
    Am J Obstet Gynecol; 2016 Mar; 214(3):385.e1-7. PubMed ID: 26928154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of integrase inhibitor use, body mass index, physical activity and caloric intake to weight gain in people living with HIV.
    Guaraldi G; Milic J; Bacchi E; Carli F; Menozzi M; Franconi I; Raimondi A; Ciusa G; Masi V; Belli M; Guaraldi S; Aprile E; Mancini M; Mussini C; Lake JE; Erlandson KM
    HIV Res Clin Pract; 2022 Nov; 24(1):1-6. PubMed ID: 36883678
    [No Abstract]   [Full Text] [Related]  

  • 19. Integrase Strand Transfer Inhibitor Start or Switch Impacts Learning in Women With HIV.
    O'Halloran JA; Wang K; Spence AB; Williams DW; Dastgheyb R; Fitzgerald KC; Kamkwalala AR; Maki PM; Sharma A; Gustafson DR; Milam J; Weber KM; Adimora AA; Ofotokun I; Fischl MA; Konkle-Parker D; Lahiri CD; Sheth AN; Xu Y; Rubin LH
    J Acquir Immune Defic Syndr; 2021 Apr; 86(5):593-599. PubMed ID: 33394812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
    Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
    Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.